Heal House Vitiligo Study 75 · Original Article
How to measure how much vitiligo treatment has improved 'in others' eyes'?
Psychometric properties of the Vitiligo Noticeability Scale using data from a phase II randomized study of upadacitinib in adults with nonsegmental vitiligo
In short
There is a questionnaire where patients directly answer 'how much less noticeable vitiligo has become to others.' This study confirmed, using new drug clinical trial data, whether this questionnaire is a reliable tool.
When assessing whether treatment has been successful, area-based measurements alone may not fully capture the changes that patients feel. In particular, 'how much less noticeable it is to others' is a very important issue for patients. The tool used to measure this is the Vitiligo Noticeability Scale. We confirmed whether this scale is truly reliable using data from a phase 2 clinical trial of a new oral drug (upadacitinib). I participated in this study as a co-investigator.
Q1 What Is the Vitiligo Noticeability Scale?
This is a questionnaire in which patients answer themselves: 'Compared to before treatment, how much less noticeable is your vitiligo?' Its key feature is that it directly captures the patient's own perception, which is difficult to capture with area measurements made by a doctor. In vitiligo, 'how noticeable it is to others' greatly affects quality of life. Therefore, assessment from this perspective is important. This study used data collected from a phase 2 clinical trial of a new drug to evaluate how reliable this questionnaire is.
Q2 What Are the Benefits of Validating This Scale?
Because a measurement tool must be reliable for the results it produces—such as 'improvement'—to be trustworthy. Validating a questionnaire involves checking two things: whether repeated questions about the same condition yield the same answers, and whether the tool properly detects changes when improvement actually occurs. Only after such validation can a tool be used to evaluate the effects of a new drug in a clinical trial from the patient's perspective. Furthermore, in clinical practice, it helps clearly record the changes that patients perceive. It is, in essence, an effort to bring the patient's voice to the center of treatment evaluation.
Closing remarks
There is a growing trend toward judging whether treatment is successful based on the patient's own perception rather than the doctor's eyes. This study added evidence that a tool for measuring that perception is reliable. It helps ensure that the patient's voice carries more weight in future vitiligo clinical trials and clinical practice. It was a meaningful work in which I participated as a co-investigator.
